APA (7th ed.) Citation

Weiss, A., Delavenne, E., Matias, C., Lagler, H., Simon, D., Li, P., . . . Rades, T. (2022). Topical niclosamide (ATx201) reduces Staphylococcus aureus colonization and increases Shannon diversity of the skin microbiome in atopic dermatitis patients in a randomized, double‐blind, placebo‐controlled Phase 2 trial. Clinical & Translational Medicine, 12(5), 1. https://doi.org/10.1002/ctm2.790

Chicago Style (17th ed.) Citation

Weiss, Anne, et al. "Topical Niclosamide (ATx201) Reduces Staphylococcus Aureus Colonization and Increases Shannon Diversity of the Skin Microbiome in Atopic Dermatitis Patients in a Randomized, Double‐blind, Placebo‐controlled Phase 2 Trial." Clinical & Translational Medicine 12, no. 5 (2022): 1. https://doi.org/10.1002/ctm2.790.

MLA (9th ed.) Citation

Weiss, Anne, et al. "Topical Niclosamide (ATx201) Reduces Staphylococcus Aureus Colonization and Increases Shannon Diversity of the Skin Microbiome in Atopic Dermatitis Patients in a Randomized, Double‐blind, Placebo‐controlled Phase 2 Trial." Clinical & Translational Medicine, vol. 12, no. 5, 2022, p. 1, https://doi.org/10.1002/ctm2.790.